Epigenetic reprogramming in breast cancer: From new targets to new therapies

Annals of Medicine

Volumn 46, Issue 6, 2014, Pages 397-408

  Katz, Tiffany A ^a   Huang, Yi ^a   Davidson, Nancy E ^a   Jankowitz, Rachel C ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Biomarkers; Breast cancer; Combination therapy; DNA methylation; DNA methyltransferase inhibitor; Epigenetic; Histone deacetylase inhibitor; Histone demethylase; Post translational modification

Indexed keywords

ANTINEOPLASTIC AGENT; DNA METHYLTRANSFERASE INHIBITOR; HISTONE DEACETYLASE INHIBITOR; LONG UNTRANSLATED RNA; MICRORNA; GENETIC MARKER; HISTONE;

BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RISK; DIET; DISEASE PREDISPOSITION; DNA METHYLATION; EPIGENETICS; GENE EXPRESSION; GENE TARGETING; GENETIC IDENTIFICATION; HISTONE ACETYLATION; HISTONE MODIFICATION; HORMONAL THERAPY; HUMAN; NUCLEAR REPROGRAMMING; OUTCOME ASSESSMENT; REVIEW; BREAST NEOPLASMS; DRUG EFFECTS; FEMALE; GENETIC EPIGENESIS; GENETIC MARKER; GENETIC PREDISPOSITION; GENETICS; RISK FACTOR;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; HISTONES; HUMANS; MICRORNAS; RISK FACTORS;

EID: 84907052081     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.3109/07853890.2014.923740     Document Type: Review

References (116)

1. Bird AP. CpG-rich islands and the function of DNA methylation. Nature. 1986 ; 321 : 209-13
2. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev. 2002 ; 16 : 6-21
3. He YF, Li BZ, Li Z, Liu P, Wang Y, Tang Q, et al. Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science. 2011; 333: 1303-7
4. Ito S, D'Alessio AC, Taranova OV, Hong K, Sowers LC, Zhang Y. Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specifi cation. Nature. 2010 ; 466 : 1129-33
5. Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y , et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science. 2009 ; 324 : 930-5
6. Yang H, Liu Y, Bai F, Zhang JY, Ma SH, Liu J, et al. Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation. Oncogene. 2013; 32: 663-9
7. Haff ner MC, Chaux A, Meeker AK, Esopi DM, Gerber J, Pellakuru LG, et al. Global 5-hydroxymethylcytosine content is signifi cantly reduced in tissue stem/progenitor cell compartments and in human cancers. Oncotarget. 2011 ; 2 : 627-37
8. van Hoesel AQ, Sato Y, Elashoff DA, Turner RR, Giuliano AE, Shamonki JM , et al. Assessment of DNA methylation status in early stages of breast cancer development. Br J Cancer. 2013; 108: 2033-8
9. Widschwendter M, Jones PA. DNA methylation and breast carcinogenesis. Oncogene. 2002; 21: 5462-82
10. S tearns V , Z hou Q , D avidson N E. E pigenetic regulation as a new target for breast cancer therapy. Cancer Invest. 2007; 25: 659-65
11. Ren M, Pozzi S, Bistulfi G, Somenzi G, Rossetti S, Sacchi N. Impaired retinoic acid (RA) signal leads to RARbeta2 epigenetic silencing and RA resistance. Mol Cell Biol. 2005; 25: 10591-603
12. Bistulfi G , P ozzi S , R en M , R ossetti S , S acchi N. A repressive epigenetic domino eff ect confers susceptibility to breast epithelial cell transformation: implications for predicting breast cancer risk. Cancer Res. 2006 ; 66 : 10308-14
13. Pruitt K, Zinn RL, Ohm JE, McGarvey KM, Kang SH, Watkins DN, et al. Inhibition of SIRT1 reactivates silenced cancer genes without loss of promoter DNA hypermethylation. PLoS Genet. 2006 ; 2 : e40
14. Ottaviano YL, Issa JP, Parl FF, Smith HS, Baylin SB, Davidson NE. Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Res. 1994 ; 54 : 2552-5
15. Nass SJ, Herman JG, Gabrielson E, Iversen PW, Parl FF, Davidson NE, et al. Aberrant methylation of the estrogen receptor and E-cadherin 5 CpG islands increases with malignant progression in human breast cancer. Cancer Res. 2000; 60: 4346-8
16. Lapidus RG, Ferguson AT, Ottaviano YL, Parl FF, Smith HS, Weitzman SA , et al. Methylation of estrogen and progesterone receptor gene 5 CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors. Clin Cancer Res. 1996 ; 2 : 805-10
17. Ferguson AT , Lapidus RG , Baylin SB , Davidson NE.. Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression. Cancer Res. 1995 ; 55 : 2279-83
18. Huang Y, Shaw PG, Davidson NE. Inhibition of histone deacetylases. Methods Mol Biol. 2011 ; 791 : 297-311
19. Muller BM, Jana L, Kasajima A, Lehmann A, Prinzler J, Budczies J, et al. Diff erential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer-overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression. BMC Cancer. 2013; 13: 215
20. H uang Y , N ayak S , J ankowitz R , D avidson N E, O esterreich S. E pigenetics in breast cancer: what's new? Breast Cancer Res. 2011; 13: 225
21. Leszinski G, Gezer U, Siegele B, Stoetzer O, Holdenrieder S. Relevance of histone marks H3K9me3 and H4K20me3 in cancer. Anticancer Res. 2012 ; 32 : 2199-205
22. Ren G, Baritaki S, Marathe H, Feng J, Park S, Beach S, et al. Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer. Cancer Res. 2012; 72: 3091-104
23. Moore HM, Gonzalez ME, Toy KA, Cimino-Mathews A, Argani P, Kleer CG. EZH2 inhibition Decreases p38 signaling and suppresses breast cancer motility and metastasis. Breast Cancer Res Treat. 2013 ; 138 : 741-52
24. Yokoyama Y, Hieda M, Nishioka Y, Matsumoto A, Higashi S, Kimura H, et al. Cancer-Associated upregulation of histone H3 lysine 9 trimethylation promotes cell motility in vitro and drives tumor formation in vivo. Cancer Sci. 2013; 104: 889-95
25. Zhu Q, Huang Y, Marton LJ, Woster PM, Davidson NE, Casero RA Jr. Polyamine analogs modulate gene expression by inhibiting lysinespecifi c demethylase 1 (LSD1) and altering chromatin structure in human breast cancer cells. Amino Acids. 2012; 42: 887-98
26. Huang Y, Vasilatos SN, Boric L, Shaw PG, Davidson NE. Inhibitors of histone demethylation and histone deacetylation cooperate in regulating gene expression and inhibiting growth in human breast cancer cells. Breast Cancer Res Treat. 2012 ; 131 : 777-89
27. Vasilatos SN, Katz TA, Oesterreich S, Wan Y, Davidson NE, Huang Y. Crosstalk between lysine-specifi c demethylase 1 (LSD1) and histone deacetylases mediates antineoplastic effi cacy of HDAC inhibitors in human breast cancer cells. Carcinogenesis. 2013; 34: 1196-207
28. Shi Y, Lan F, Matson C, Mulligan P, Whetstine JR, Cole PA, et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell. 2004; 119: 941-53
29. Lee MG, Wynder C, Cooch N, Shiekhattar R. An essential role for CoREST in nucleosomal histone 3 lysine 4 demethylation. Nature. 2005 ; 437 : 432-5
30. Garcia-Bassets I, Kwon YS, Telese F, Prefontaine GG, Hutt KR, Cheng CS, et al. Histone methylation-dependent mechanisms impose ligand dependency for gene activation by nuclear receptors. Cell. 2007 ; 128 : 505-18
31. Lim S, Janzer A, Becker A, Zimmer A, Schule R, Buettner R, et al. Lysine-specifi c demethylase 1 (LSD1) is highly expressed in ERnegative breast cancers and a biomarker predicting aggressive biology. Carcinogenesis. 2010; 31: 512-20
32. Metzger E, Wissmann M, Yin N, Muller J, Schneider R, Peters A, et al. LSD1 demethylates repressive histone marks to promote androgenreceptor-dependent transcription. Nature. 2005; 437: 436-9
33. Huang Y, Marton LJ, Woster PM, Casero RA. Polyamine analogues targeting epigenetic gene regulation. Essays Biochem. 2009; 46: 95-110
34. Serce N, Gnatzy A, Steiner S, Lorenzen H, Kirfel J, Buettner R. Elevated expression of LSD1 (Lysine-specifi c demethylase 1) during tumour progression from pre-invasive to invasive ductal carcinoma of the breast. BMC Clin Pathol. 2012; 12: 13
35. Ciccone DN, Su H, Hevi S, Gay F, Lei H, Bajko J, et al. KDM1B is a histone H3K4 demethylase required to establish maternal genomic imprints. Nature. 2009; 461: 415-18
36. R amadoss S , C hen X , W ang C Y. H istone demethylase KDM6B promotes epithelial-mesenchymal transition. J Biol Chem. 2012 ; 287 : 44508-17
37. Y u N , H uangyang P , Y ang X , H an X , Y an R , J ia H , e t a l m icroRNA-7 suppresses the invasive potential of breast cancer cells and sensitizes cells to DNA damages by targeting histone methyltransferase SET8. J Biol Chem. 2013 ; 288 : 19633-42
38. Zhang Y, Eades G, Yao Y, Li Q, Zhou Q. Estrogen receptor alpha signaling regulates breast tumor-initiating cells by down-regulating miR-140 which targets the transcription factor SOX2. J Biol Chem. 2012 ; 287 : 41514-22
39. Rhodes LV, Nitschke AM, Segar HC, Martin EC, Driver JL, Elliott S, et al. The histone deacetylase inhibitor trichostatin A alters microRNA expression profi les in apoptosis-resistant breast cancer cells. Oncol Rep. 2012 ; 27 : 10-16
40. Wang S, Huang J, Lyu H, Lee CK, Tan J, Wang J, et al. Functional cooperation of miR-125a, miR-125b, and miR-205 in entinostatinduced downregulation of erbB2/erbB3 and apoptosis in breast cancer cells. Cell Death Dis. 2013 ; 4 : e556
41. Tsai MC, Manor O, Wan Y, Mosammaparast N, Wang JK, Lan F, et al. Long noncoding RNA as modular scaff old of histone modifi cation complexes. Science. 2010; 329: 689-93
42. Alves CP, Fonseca AS, Muys BR, de Barros ELBR, Burger MC, de Souza JE, et al. The lincRNA Hotair is required for epithelial-Tomesenchymal transition and stemness maintenance of cancer cells lines. Stem Cells. 2013; 31: 2827-32
43. Reik W, Dean W, Walter J. Epigenetic reprogramming in mammalian Development. Science. 2001; 293: 1089-93
44. Kafri T, Ariel M, Brandeis M, Shemer R, Urven L, McCarrey J, et al. Developmental pattern of gene-specifi c DNA methylation in the mouse embryo and germ line. Genes Dev. 1992; 6: 705-14
45. Santos F, Dean W. Epigenetic reprogramming during early development in mammals. Reproduction. 2004; 127: 643-51
46. Fernandez-Twinn DS, Ekizoglou S, Gusterson BA, Luan J, Ozanne SE. Compensatory mammary growth following protein restriction During pregnancy and lactation increases early-onset mammary tumor incidence in rats. Carcinogenesis. 2007; 28: 545-52
47. Lillycrop KA, Slater-Jeff eries JL, Hanson MA, Godfrey KM, Jackson AA, Burdge GC. Induction of altered epigenetic regulation of the hepatic glucocorticoid receptor in the off spring of rats fed a protein-restricted diet during pregnancy suggests that reduced DNA methyltransferase-1 expression is involved in impaired DNA methylation and changes in histone modifi cations. Br J Nutr. 2007; 97: 1064-73
48. Lillycrop KA, Phillips ES, Torrens C, Hanson MA, Jackson AA, Burdge GC. Feeding pregnant rats a protein-restricted diet persistently alters the methylation of specifi c cytosines in the hepatic PPAR alpha promoter of the off spring. Br J Nutr. 2008; 100: 278-82
49. K ovacheva V P, D avison J M, M ellott T J, R ogers A E, Y ang S , O Brien M J, et al. Raising gestational choline intake alters gene expression in DMBA-evoked mammary tumors and prolongs survival. FASEB J. 2009 ; 23 : 1054-63
50. Zheng S, Rollet M, Yang K, Pan YX. A gestational low-protein Diet represses p21(WAF1/Cip1) expression in the mammary gland of off spring rats through promoter histone modifi cations. Br J Nutr. 2012 ; 108 : 998-1007
51. de Assis S, Warri A, Cruz MI, Laja O, Tian Y, Zhang B, et al. High-fat or ethinyl-oestradiol intake during pregnancy increases mammary cancer risk in several generations of off spring. Nat Commun. 2012 ; 3 : 1053
52. Barker DJ. The origins of the developmental origins theory. J Intern Med. 2007; 261: 412-17
53. Hilakivi-Clarke L, Cabanes A, de Assis S, Wang M, Khan G, Shoemaker WJ , et al. In utero alcohol exposure increases mammary tumorigenesis in rats. Br J Cancer. 2004; 90: 2225-31
54. Polanco TA, Crismale-Gann C, Reuhl KR, Sarkar DK, Cohick WS. Fetal alcohol exposure increases mammary tumor susceptibility and alters tumor phenotype in rats. Alcohol Clin Exp Res. 2010; 34: 1879-87
55. Bekdash RA, Zhang C, Sarkar DK. Gestational choline supplementation normalized fetal alcohol-induced alterations in histone modifi cations, DNA methylation, and proopiomelanocortin (POMC) gene expression in beta-endorphin-producing POMC neurons of the hypothalamus. Alcohol Clin Exp Res. 2013; 37: 1133-42
56. Hilakivi-Clarke L, de Assis S. Fetal origins of breast cancer. Trends Endocrinol Metab. 2006; 17: 340-8
57. Rijnkels M, Kabotyanski E, Montazer-Torbati MB, Hue Beauvais C, Vassetzky Y , Rosen JM , et al. The epigenetic landscape of mammary gland development and functional diff erentiation. J Mammary Gland Biol Neoplasia. 2010 ; 15 : 85-100
58. G uerrero-Bosagna C , S kinner M K. E nvironmentally induced epigenetic transgenerational inheritance of phenotype and disease. Mol Cell Endocrinol. 2012; 354: 3-8
59. Anway MD, Cupp AS, Uzumcu M, Skinner MK. Epigenetic transgenerational actions of endocrine disruptors and male fertility. Science. 2005 ; 308 : 1466-9
60. Skinner MK. Endocrine disruptors and epigenetic transgenerational disease etiology. Pediatr Res. 2007; 61(5 Pt 2): 48R-50R.
61. Duthie SJ, Narayanan S, Sharp L, Little J, Basten G, Powers H. Folate, DNA stability and colo-rectal neoplasia. Proc Nutr Soc. 2004 ; 63 : 571-8
62. Kim YI. Folate and DNA methylation: a mechanistic link between folate defi ciency and colorectal cancer? Cancer Epidemiol Biomarkers Prev. 2004 ; 13 : 511-19
63. Duthie SJ. Folate and cancer: how DNA damage, repair and methylation impact on colon carcinogenesis. J Inherit Metab Dis. 2011 ; 34 : 101-9
64. Bistulfi G, Vandette E, Matsui S, Smiraglia DJ. Mild folate defi ciency induces genetic and epigenetic instability and phenotype changes in prostate cancer cells. BMC Biol. 2010; 8: 6
65. S tefanska B , K arlic H , V arga F , F abianowska-Majewska K , Haslberger A. Epigenetic mechanisms in anti-cancer actions of bioactive food components-The implications in cancer prevention. Br J Pharmacol. 2012; 167: 279-97
66. Ghoshal K, Li X, Datta J, Bai S, Pogribny I, Pogribny M, et al. A folateand methyl-defi cient diet alters the expression of DNA methyltransferases and methyl CpG binding proteins involved in epigenetic gene silencing in livers of F344 rats. J Nutr. 2006; 136: 1522-7
67. Gong Z, Ambrosone CB, McCann SE, Zirpoli G, Chandran U, Hong CC , et al. Associations of dietary folate, vitamins B6 and B12 and methionine intake with risk of breast cancer among African American and European American women. Int J Cancer. 2014; 134: 1422-35
68. Bassett JK, Baglietto L, Hodge AM, Severi G, Hopper JL, English DR, et al. Dietary intake of B vitamins and methionine and breast cancer risk. Cancer Causes Control. 2013; 24: 1555-63
69. Yang D, Baumgartner RN, Slattery ML, Wang C, Giuliano AR, Murtaugh MA, et al. Dietary intake of folate, B-vitamins and methionine and breast cancer risk among Hispanic and non-Hispanic white women. PLoS One. 2013; 8: e54495
70. Xu X, Gammon MD, Zeisel SH, Lee YL, Wetmur JG, Teitelbaum SL, et al. Choline metabolism and risk of breast cancer in a populationbased study. FASEB J. 2008; 22: 2045-52
71. Pledgie-Tracy A, Sobolewski MD, Davidson NE. Sulforaphane induces cell type-specifi c apoptosis in human breast cancer cell lines. Mol Cancer Ther. 2007; 6: 1013-21
72. Zhang Y, Kensler TW, Cho CG, Posner GH, Talalay P. Anticarcinogenic activities of sulforaphane and structurally related synthetic norbornyl isothiocyanates. Proc Natl Acad Sci U S A. 1994; 91: 3147-50
73. Liu H, Talalay P. Relevance of anti-infl ammatory and antioxidant activities of exemestane and synergism with sulforaphane for disease prevention. Proc Natl Acad Sci U S A. 2013 ; 110 : 19065-70
74. W idschwendter M , A postolidou S , R aum E , R othenbacher D , F iegl H , Menon U , et al. Epigenotyping in peripheral blood cell DNA and breast cancer risk: a proof of principle study. PLoS One. 2008; 3: e2656
75. Xu X, Gammon MD, Hernandez-Vargas H, Herceg Z, Wetmur JG, Teitelbaum SL , et al. DNA methylation in peripheral blood measured by LUMA is associated with breast cancer in a population-based study. FASEB J. 2012 ; 26 : 2657-66
76. Dumitrescu RG, Marian C, Krishnan SS, Spear SL, Kallakury BV, Perry DJ , et al. Familial and racial determinants of tumour suppressor genes promoter hypermethylation in breast tissues from healthy women. J Cell Mol Med. 2010; 14: 1468-75
77. Xu Z, Bolick SC, DeRoo LA, Weinberg CR, Sandler DP, Taylor JA. Epigenome-wide association study of breast cancer using prospectively collected sister study samples. J Natl Cancer Inst. 2013 ; 105 : 694-700
78. Graff JR, Herman JG, Lapidus RG, Chopra H, Xu R, Jarrard DF, et al. E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res. 1995; 55: 5195-9
79. Suzuki H, Toyota M, Carraway H, Gabrielson E, Ohmura T, Fujikane T , et al. Frequent epigenetic inactivation of Wnt antagonist genes in breast cancer. Br J Cancer. 2008; 98: 1147-56
80. Yoo CB, Jeong S, Egger G, Liang G, Phiasivongsa P, Tang C, et al. Delivery of 5-Aza-2 -deoxycytidine to cells using oligodeoxynucleotides. Cancer Res. 2007; 67: 6400-8
81. Byun HM , Choi SH , Laird PW , Trinh B , Siddiqui MA , Marquez VE, et al. 2-Deoxy-N4-[2-(4-nitrophenyl)ethoxycarbonyl]-5-Azacytidine: a novel inhibitor of DNA methyltransferase that requires activation by human carboxylesterase 1. Cancer Lett. 2008 ; 266 : 238-48
82. Hurd PJ, Whitmarsh AJ, Baldwin GS, Kelly SM, Waltho JP, Price NC, et al. Mechanism-based inhibition of C5-cytosine DNA methyltransferases by 2-H pyrimidinone. J Mol Biol. 1999; 286: 389-401
83. Billam M, Sobolewski MD, Davidson NE. Eff ects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells. Breast Cancer Res Treat. 2010 ; 120 : 581-92
84. Sharma D, Saxena NK, Davidson NE, Vertino PM. Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes. Cancer Res. 2006; 66: 6370-8
85. Keen JC, Yan L, Mack KM, Pettit C, Smith D, Sharma D, et al. A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-Aza 2 -deoxycytidine. Breast Cancer Res Treat. 2003 ; 81 : 177-86
86. Zhou Q, Atadja P, Davidson NE. Histone deacetylase inhibitor LBH589 reactivates silenced estrogen receptor alpha (ER) gene expression without loss of DNA hypermethylation. Cancer Biol Ther. 2007 ; 6 : 64-9
87. Yang X, Ferguson AT, Nass SJ, Phillips DL, Butash KA, Wang SM, et al. Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition. Cancer Res. 2000 ; 60 : 6890-4
88. Leurs U, Clausen RP, Kristensen JL, Lohse B. Inhibitor scaff old for the histone lysine demethylase KDM4C (JMJD2C). Bioorg Med Chem Lett. 2012 ; 22 : 5811-13
89. Wang L, Chang J, Varghese D, Dellinger M, Kumar S, Best AM, et al. A small molecule modulates Jumonji histone demethylase activity and selectively inhibits cancer growth. Nat Commun. 2013; 4: 2035
90. Tan J, Yang X, Zhuang L, Jiang X, Chen W, Lee PL, et al. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev. 2007 ; 21 : 1050-63
91. Puppe J, Drost R, Liu X, Joosse SA, Evers B, Cornelissen-Steijger P, et al. BRCA1-defi cient mammary tumor cells are dependent on EZH2 expression and sensitive to Polycomb Repressive Complex 2-inhibitor 3-deazaneplanocin A. Breast Cancer Res. 2009; 11: R63
92. Qi W, Chan H, Teng L, Li L, Chuai S, Zhang R, et al. Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc Natl Acad Sci U S A. 2012 ; 109 : 21360-5
93. Knutson SK, Wigle TJ, Warholic NM, Sneeringer CJ, Allain CJ, Klaus CR , et al. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat Chem Biol. 2012 ; 8 : 890-6
94. McCabe MT, Ott HM, Ganji G, Korenchuk S, Th ompson C, Van Aller GS , et al. EZH2 inhibition as a therapeutic strategy for lymphoma wiTheZH2-Activating mutations. Nature. 2012 ; 492 : 108-12
95. Cooper SJ, von Roemeling CA, Kang KH, Marlow LA, Grebe SK, Menefee ME , et al. Reexpression of tumor suppressor, sFRP1, leads to antitumor synergy of combined HDAC and methyltransferase inhibitors in chemoresistant cancers. Mol Cancer Ther. 2012; 11: 2105-15
96. Vijayaraghavalu S, Dermawan JK, Cheriyath V, Labhasetwar V. Highly synergistic eff ect of sequential treatment wiThepigenetic and anticancer drugs to overcome drug resistance in breast cancer cells is mediated via activation of p21 gene expression leading to G2/M cycle arrest. Mol Pharm. 2013; 10: 337-52
97. Li Y, Meeran SM, Patel SN, Chen H, Hardy TM, Tollefsbol TO. Epigenetic reactivation of estrogen receptor-Alpha (ERalpha) by genistein enhances hormonal therapy sensitivity in ERalpha-negative breast cancer. Mol Cancer. 2013; 12: 9
98. Liu K, Cang S, Ma Y, Chiao JW. Synergistic eff ect of paclitaxel and epigenetic agent phenethyl isothiocyanate on growth inhibition, cell cycle arrest and apoptosis in breast cancer cells. Cancer Cell Int. 2013 ; 13 : 10
99. Th akur S, Feng X, Qiao Shi Z, Ganapathy A, Kumar Mishra M, Atadja P , et al. ING1 and 5-Azacytidine act synergistically to block breast cancer cell growth. PLoS One. 2012; 7: e43671
100. Yang X, Phillips DL, Ferguson AT, Nelson WG, Herman JG, Davidson NE. Synergistic activation of functional estrogen receptor (ER)-Alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-Alpha-negative breast cancer cells. Cancer Res. 2001 ; 61 : 7025-9
101. Sharma D, Saxena NK, Davidson NE, Vertino PM. Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes. Cancer Res. 2006; 66: 6370-8
102. Luu TH , Morgan RJ , Leong L , Lim D , McNamara M. , Portnow J, et al. A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study. Clin Cancer Res. 2008; 14: 7138-42
103. Stearns V, Jacobs LK, Fackler M, Tsangaris TN, Rudek MA, Higgins M, et al. Biomarker modulation following short-Term vorinostat in women with newly diagnosed primary breast cancer. Clin Cancer Res. 2013 ; 19 : 4008-16
104. C onnolly R M, J ankowitz R C, Z ahnow C A, Z hang Z , R udek M A, Jeter SC, et al. A phase 2 study investigating the safety, effi cacy and surrogate biomarkers of response of 5-Azacitidine (5-AZA) andentinostat (MS-275) in patients with triple-negative advanced breast cancer. Cancer Res. 2013; 73(8 Suppl 1
105. Munster PN, Th urn K T, Th omas S, Raha P, Lacevic M, Miller A, et al. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer. 2011; 104: 1828-35
106. Wardley AM, Stein R, McCaff rey J, Crown J, Malik Z, Rea D, Barrett-Lee PJ , et al. Phase II data for entinostat, a class 1 selective histone deacetylase inhibitor, in patients whose breast cancer is progressing on aromatase inhibitor therapy. 2010 ASCO Annual Meeting Abstract. J Clin Oncol. 2010; 28(15 suppl): 1052
107. Y ardley D A, I smail-Khan R R, M elichar B , L ichinitser M , M unster P N, Klein PM, et al. Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. J Clin Oncol. 2013; 31: 2128-35
108. Tan W, Allred JB, Moreno-Aspitia A, Northfelt DW, Ingle JN, Perez EA. Phase I study of panobinostat (LBH589) and letrozole in post-menopausal women with metastatic breast cancer. J Clin Oncol. 2012; 30(suppl); abstr e13501
109. Linden HM, Kurland BF, Link J, Gadi VK, Specht JM, Gralow J, et al. Vorinostat to restore sensitivity to aromatase inhibitor therapy in metastatic breast cancer: a phase II clinical trial wiTheR imaging correlates. J Clin Oncol. 2012; 30(suppl): abstr TPS3109
110. Arce C, Perez-Plasencia C, Gonzalez-Fierro A, de la Cruz-Hernandez E, Revilla-Vazquez A, Chavez-Blanco A, et al. A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer. PLoS One. 2006 ; 1 : e98
111. Ramaswamy B, Fiskus W, Cohen B, Pellegrino C, Hershman DL, Chuang E , et al. Phase I-II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostatinduced tubulin acetylation and Hsp90 inhibition in vivo. Breast Cancer Res Treat. 2012 ; 132 : 1063-72
112. Trepel J, Mollapour M, Giaccone G, Neckers L. Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer. 2010; 10: 537-49
113. James ES, Chung GG, DiGiovanna M, Sanft TB, Hofstatter EW, Sowers N , et al. Phase I study of the HDAC inhibitor vorinostat in combination with capecitabine in a biweekly schedule in advanced breast cancer. J Clin Oncol 2013; 31(suppl); abstr 2587
114. Connolly RM, Jeter S, Zorzi J, Zhang Z, Armstrong DK, Fetting JH, et al. A multi-institutional double-blind phase II study evaluating response and surrogate biomarkers to carboplatin and nab-paclitaxel (CP) with or without vorinostat as preoperative systemic therapy (PST) in HER2-negative primary operable breast cancer (TBCRC008). 2010 ASCO Annual Meeting Abstracts. J Clin Oncol. 2010; 28(15 suppl): TPS111
115. Swaby R, Sparano J, Bhalla K, Meropol N, Falkson C, Pellegrino C, et al. A phase II study of the histone deacetylase inhibitor, vorinostat, in combination with trastuzumab in patients with advanced metastatic and/or local chest wall recurrent HER-2 amplifi ed breast cancer resistant to transtuzumab-containing therapy: (E1104) a trial of the Eastern Cooperative Oncology Group. Cancer Res. 2009 ; 69(24 Suppl) : 5084
116. Karytinos A, Forneris F, Profumo A, Ciossani G, Battaglioli E, Binda C, et al. A novel mammalian fl avin-dependent histone demethylase. J Biol Chem. 2009; 284: 17775-82